Skip to content

002365.SZ

Qianjiang Yongan Pharmaceutical Co., Ltd.

SZSE · Healthcare · C 制造业 · CN

CNY 15.11
−8.92%
Ask drillr

Year over year

Reported trailing growth

Revenue
+4.3%
EBITDA
EBIT
-8.9%
EPS
+23.0%
Free cash flow
-4.4%
Operating cash flow
-16.5%

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS

Three-year CAGR

Revenue
-18.8%
EBITDA
-22.7%
EBIT
-58.8%
Net income
-45.7%
EPS
-45.4%
Free cash flow
-31.4%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026